Effect of mast cell stabilizers in hyperhomocysteinemia-induced cardiac hypertrophy in rats

Journal of Cardiovascular Pharmacology

Volumn 51, Issue 6, 2008, Pages 596-604

  Singh, Amrit Pal ^b   Singh, Manjeet ^b   Balakumar, Pitchai ^a,b  

^a PUNJABI UNIVERSITY   (India)

^b ISF Institute of Pharmaceutical Sciences and Drug Research   (India)

Author keywords

Cardiac hypertrophy; Hyperhomocysteinemia; Ketotifen; Mast cells; Sodium cromoglycate

Indexed keywords

COLLAGEN; CROMOGLYCATE DISODIUM; GLUTATHIONE; HOMOCYSTEINE; KETOTIFEN; METHIONINE; SUPEROXIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CELL DENSITY; CELL SIZE; CONTROLLED STUDY; DRUG EFFECT; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HYPERHOMOCYSTEINEMIA; LIPID PEROXIDATION; MALE; MAST CELL; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CONTENT; RAT; STAINING; TREATMENT DURATION; ANIMAL; BIOSYNTHESIS; BLOOD PRESSURE; DRUG COMBINATION; HEART LEFT VENTRICLE HYPERTROPHY; PATHOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; BLOOD PRESSURE; COLLAGEN; CROMOLYN SODIUM; DRUG THERAPY, COMBINATION; HYPERHOMOCYSTEINEMIA; HYPERTROPHY, LEFT VENTRICULAR; KETOTIFEN; MALE; MAST CELLS; METHIONINE; OXIDATIVE STRESS; RATS; RATS, WISTAR;

EID: 53249144566     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31817ae60f     Document Type: Article

References (53)

1. Mendez GF, Cowie MR. The epidemiological features of heart failure in developing countries: a review of the literature. Int J Cardiol. 2001;80: 213-219.
2. Murray-Thomas T, Cowie MR. Epidemiology and clinical aspects of congestive heart failure. J Renin Angiotensin Aldosterone Syst. 2003;4: 131-136.
3. Balakumar P, Singh M. Possible role of poly (ADP-ribose) polymerase in pathological and physiological cardiac hypertrophy. Meth Find Exp Clin Pharmacol. 2006;28:683-689.
4. Balakumar P, Singh AP, Singh M. Rodent models of heart failure. J Pharmacol Toxicol Meth. 2007;56:1-10.
5. Finkelstein JD, Martin JJ. Homocysteine. Int J Biochem Cell Biol. 2000; 32:385-389.
6. Boers GH. Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease. Semin Thromb Hemost. 2000;26:291-295.
7. Balakumar P, Singh AP, Ganti SS, Singh M. Hyperhomocysteinemia and cardiovascular disorders: is there a correlation? Trends Med Res. 2007;2: 160-166.
8. Blacher J, Demuth K, Guerin AP, et al. Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol. 1999;12:248-255.
9. Joseph J, Joseph L, Shekhawat NS, et al. Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats. Am J Physiol Heart Circ Physiol. 2003;285:H679-H686.
10. Devi S, Kennedy RH, Joseph L, et al. Effect of long-term hyperhomoysteinemia on myocardial structure and function in hypertensive rats. Cardiovasc Pathol. 2006;15:75-82.
11. Shiota N, Rysa J, Kovanen PT, et al. A role for cardiac mast cells in the pathogenesis of hypertensive heart disease. J Hypertens. 2003;21:1935-1944.
12. Brower GL, Janicki JS. Pharmacologic inhibition of mast cell degranulation prevents left ventricular remodeling induced by chronic volume overload in rats. J Card Fail. 2005;11:548-556.
13. Balakumar P, Singh AP, Ganti SS, et al. Resident cardiac mast cells: are they culprit in the pathogenesis of cardiac hypertrophy? Basic Clin Pharmacol Toxicol. 2008;102:5-9.
14. Barka T, van der Noen H, Shaw PA. Proto-oncogene fos (c-fos) expression in the heart. Oncogene. 1987;1:439-443.
15. Palaniyandi Selvaraj S, Watanabe K, Ma M, et al. Involvement of mast cells in the development of fibrosis in rats with postmyocarditis dilated cardiomyopathy. Biol Pharm Bull. 2005;28:2128-2132.
16. Mackins CJ, Kano S, Seyedi N, et al. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest. 2006;116:1063-1070.
17. Miyazaki M, Takai S, Jin D, et al. Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models. Pharmacol Ther. 2006;112:668-676.
18. Mori T, Chen YF, Feng JA, et al. Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse. Cardiovasc Res. 2004;61:771-779.
19. Simko F, Pelouch V, Kyselovic J. Captopril fails to reverse hypertrophy of the left ventricle induced by aortic insufficiency in rabbits. Physiol Res. 2002;51:27-33.
20. Balakumar P, Singh M. Effect of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase in experimental cardiac hypertrophy. Internatl J Pharmacol. 2006b;2:543-548.
21. Balakumar P, Singh M. Differential role of rho-kinase in pathological and physiological cardiac hypertrophy in rats. Pharmacology. 2006c;78: 91-97.
22. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thio-barbituric acid reaction. Anal Biochem. 1979;95:351-358.
23. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with folin-phenol reagent. J Biol Chem. 1951;193:265-275.
24. Beutler E, Duron O, Kelly BM. Improved method for the determination of blood glutathione. J Lab Clin Med. 1963;6:882-888.
25. Wang HD, Pagano PJ, Du Y, et al. Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circ Res. 1998;82:810-818.
26. Tokaoka H, Esposito G, Hao L, et al. Heart size independent analysis of myocardial function in murine pressure overload hypertrophy. Am J Physiol Heart Circ Physiol. 2002;282:H2190-H2197.
27. Balakumar P, Singh M. The possible role of TNF-a in physiological and pathophysiological cardiac hypertrophy in rats. Iran J Pharmacol Ther. 2005 4:138-142.
28. Zechner D, Thuerauf DJ, Hanford DS, et al. A role for the p38 mitogenactivated protein kinase pathway in myocardial cell growth, sarcomeric organization, and cardiac-specific gene expression. J Cell Biol. 1997;139: 115-127.
29. Watkins SJ, Jonker L, Arthur HM. A direct interaction between TGFbeta activated kinase 1 and the TGFbeta type II receptor: implications for TGFbeta signalling and cardiac hypertrophy. Cardiovasc Res. 2006;69: 432-439.
30. Beckles DL, Mascareno E, Siddiqui MA. Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy. Vascul Pharmacol. 2006;45:350-357.
31. Pillai JB, Gupta M, Rajamohan SB, et al. Poly (ADP-ribose) polymerase1-deficent mice are protected from angiotensin II-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2006;291:H1545-H1553.
32. Balakumar P, Singh M. The possible role of caspase-3 in pathological and physiological cardiac hypertrophy in rats. Basic Clin Pharmacol Toxicol.2006;99:418-424.
33. Ye P, Sheng L, Zhang C, et al. Atorvastatin attenuating down-regulation of peroxisome proliferator-activated receptor gamma in preventing cardiac hypertrophy of rats in vitro and in vivo. J Pharm Pharm Sci. 2006;9: 365-375.
34. Yonetci N, Oruc N, Ozutemiz AO, et al. Effects of mast-cell stabilization in cerulein-induced acute pancreatitis in rats. Int J Pancreatol. 2001;29: 163-171.
35. Gilles S, Zahler S, Welsch U, et al. Release of TNF-alpha during myocardial reperfusion depends on oxidative stress and is prevented by mast cell stabilizers. Cardiovasc Res. 2003;60:608-616.
36. Dvorak AM. Mast-cell degranulation in human hearts. N Engl J Med. 1986;315:969-970.
37. McEuen AR, Sharma B, Walls AF. Regulation of the activity of human chymase during storage and release from mast cells: the contributions of inorganic cations, pH, heparin and histamine. Biochim Biophys Acta. 1995;1267:115-121.
38. Frangogiannis NG, Lindsey ML, Michael LH, et al. Resident cardiac mast cells degranulate and release preformed TNF-alpha, initiating the cytokine cascade in experimental canine myocardial ischemia/reperfusion. Circulation. 1998;98:699-710.
39. Lim JY, Park SJ, Hwang HY, et al. TGF-beta1 induces cardiac hypertrophic responses via PKC-dependent ATF-2 activation. J Mol Cell Cardiol. 2005;39:627-636.
40. Silver RB, Reid AC, Mackins CJ, et al. Mast cells: a unique source of renin. Proc Natl Acad Sci U S A. 2004;101:13607-13612.
41. Ungvari Z, Csiszar A, Edwards JG, et al. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol. 2003;23:418-424.
42. Wolfreys K, Oliveira DB. Alterations in intracellular reactive oxygen species generation and redox potential modulate mast cell function. Eur J Immunol. 1997;27:297-306.
43. Suzuki Y, Yoshimaru T, Matsui T, et al. FceRI signaling of mast cells activates intracellular production of hydrogen peroxide: role in the regulation of calcium signals. J Immunol. 2003;171:6119-6127.
44. Swindle EJ, Metcalfe DD, Coleman JW. Rodent and human mast cells produce functionally significant intracellular reactive oxygen species but not nitric oxide. J Biol Chem. 2004;279:48751-48759.
45. Li JM, Mullen AM, Yun S, et al. Essential role of the NADPH oxidase subunit p47(phox) in endothelial cell superoxide production in response to phorbol ester and tumor necrosis factor-alpha. Circ Res. 2002;90:143-150.
46. Li JM, Shah AM. Mechanism of endothelial cell NADPH oxidase activation by ngiotensin II. Role of the p47phox subunit. J Biol Chem. 2003;278:12094-12100.
47. Ozer MK, Parlakpinar H, Cigremis Y, et al. Ischemia-reperfusion leads to depletion of glutathione content and augmentation of malondialdehyde production in the rat heart from overproduction of oxidants: can caffeic acid phenethyl ester (CAPE) protect the heart? Mol Cell Biochem. 2005;273: 169-175.
48. Mudd SH, Finkelstein JD, Irreverre F, et al. Transsulfuration in mammals. Microassays and tissue distributions of three enzymes of the pathway. J Biol Chem. 1965;240:4382-4392.
49. Chen P, Poddar R, Tipa EV, et al. Homocysteine metabolism in cardiovascular cells and tissues: implications for hyperhomocysteinemia and cardiovascular disease. Adv Enzyme Regul. 1999;39: 93-109.
50. Di Giuseppe D, Di Simplicio P, Capecchi PL, et al. Alteration in the redox state of plasma in heart-transplant patients with moderate hyperhomocysteinemia. J Lab Clin Med. 2003;142:21-28.
51. Akgul A, Skrabal CA, Thompson LO, et al. Role of mast cells and their mediators in failing myocardium under mechanical ventricular support. J Heart Lung Transplant. 2004;23:709-715.
52. Joseph J, Kennedy RH, Devi S, et al. Protective role of mast cells in homocysteine-induced cardiac remodeling. Am J Physiol Heart Circ Physiol. 2005;288:H2541-H2545.
53. Batlle M, Roig E, Perez-Villa F, et al. Increased expression of the reninangiotensin system and mast cell density but not of angiotensinconverting enzyme II in late stages of human heart failure. J Heart Lung Transplant. 2006;25:1117-1125.